TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Recruiting now · Phase 1
Conditions studied: Cancer
In brief
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Key facts
- Study ID
- NCT04485013
- Run by
- Tizona Therapeutics, Inc
- People needed
- 240
- Starts
- 2020-07-14
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2026-02-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Oklahoma — Oklahoma City, Oklahoma, United States (enrolling)
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States (enrolling)
- START Midwest — Grand Rapids, Michigan, United States (enrolling)
- Sarah Cannon Research Institute — Nashville, Tennessee, United States (enrolling)
- Rocky Mountain Cancer Centers — Denver, Colorado, United States (enrolling)
- Regions Hospital Cancer Care Center — Saint Paul, Minnesota, United States (enrolling)
- Texas Oncology - Dallas — Dallas, Texas, United States (enrolling)
- START Dallas — Fort Worth, Texas, United States (enrolling)
- Florida Cancer Specialists — Daytona Beach, Florida, United States (enrolling)
- University of Cincinnati — Cincinnati, Ohio, United States (enrolling)
- Ocala Oncology Center — Ocala, Florida, United States (enrolling)
- Texas Oncology - Paris — Paris, Texas, United States (enrolling)
- Maryland Oncology Hematology — Silver Spring, Maryland, United States (enrolling)
- NEXT Oncology Virginia — Fairfax, Virginia, United States (enrolling)
- Nebraska Cancer Center Oncology Hematology West P.C. — Omaha, Nebraska, United States (enrolling)
- American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders — Bethesda, Maryland, United States (enrolling)
- Hoag Memorial Hospital — Newport Beach, California, United States
- Yale Cancer Center — New Haven, Connecticut, United States
- Christiana Care Helen F. Graham Cancer Center — Newark, Delaware, United States
- John Hopkins Kimmer Cancer Center — Washington D.C., District of Columbia, United States
- Florida Cancer Specialists — Fleming Island, Florida, United States
- AdventHealth Research Institute — Orlando, Florida, United States
- Illinois Cancer Specialists — Arlington Heights, Illinois, United States
- University of Illinois — Chicago, Illinois, United States
- Indiana University — Indianapolis, Indiana, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.